George Valdez, MD
Family Medicine · Tomball, TXNPI 1215970876
Payments from drug & device makers
Across 147 payments — averaging $17.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$223
- Pfizer$222
- GSK$218
- Astellas Pharma US Inc$216
- AstraZeneca$173
- Sanofi-aventis U.S. LLC$133
- plus $1K from 25 others
What the payments were for
- Food & beverage$2,43897%
- Education$713%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 17 | $223 |
| Pfizer | 21 | $222 |
| GSK | 9 | $218 |
| Astellas Pharma US Inc | 9 | $216 |
| AstraZeneca | 11 | $173 |
| Sanofi-aventis U.S. LLC | 9 | $133 |
| Kowa Pharmaceuticals America, Inc. | 1 | $122 |
| Boehringer Ingelheim | 7 | $114 |
| Lilly USA, LLC | 7 | $95 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $86 |
| Sunovion Pharmaceuticals Inc. | 7 | $86 |
| Johnson & Johnson | 4 | $80 |
| AbbVie(2 entities) | 5 | $78 |
| Amarin Pharma, Inc. | 4 | $78 |
| Amgen | 4 | $72 |
| Shire North American Group Inc | 4 | $62 |
| SK Life Science, Inc. | 1 | $59 |
| Boston Scientific | 3 | $57 |
| Mylan Specialty L.p. | 3 | $53 |
| Jazz Pharmaceuticals Inc. | 2 | $46 |
| Endo Pharmaceuticals Inc. | 2 | $38 |
| Antares Pharma, Inc. | 2 | $35 |
| Arbor Pharmaceuticals, Inc. | 2 | $30 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $27 |
| Hikma Pharmaceuticals USA | 1 | $18 |
| Strongbridge US Inc. | 1 | $17 |
| Eisai Inc. | 1 | $17 |
| Radius Health, Inc. | 1 | $16 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$125
- Seglentis$122
How this compares
$2,509 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 619 | $362,790 |
| XareltoRivaroxaban | 129 | $70,764 |
| MyrbetriqMirabegron | 153 | $67,217 |
| JanuviaSitagliptin Phosphate | 103 | $51,324 |
| FarxigaDapagliflozin Propanediol | 50 | $36,272 |
| EntrestoSacubitril/Valsartan | 45 | $28,952 |
| Memantine Hcl | 578 | $26,752 |
| RexultiBrexpiprazole | 23 | $26,225 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $23,061 |
| JardianceEmpagliflozin | 27 | $20,425 |
| Potassium Chloride | 712 | $19,899 |
| TradjentaLinagliptin | 45 | $19,365 |
| LinzessLinaclotide | 24 | $17,766 |
| Atorvastatin Calcium | 1,308 | $17,081 |
| Levothyroxine Sodium | 1,383 | $16,402 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $222 | $374,157646 claims |
| Johnson & JohnsonXarelto | $80 | $70,764129 claims |
| Astellas Pharma US IncMyrbetriq | $216 | $67,217153 claims |
| Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat | $114 | $48,38989 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $218 | $45,36475 claims |
| AstraZenecaFarxiga | $173 | $36,27250 claims |
| AbbVieLinzess | $78 | $17,76624 claims |
| Novo NordiskOzempic | $223 | $12,58813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Tomball
- Earl MartinTomball$30.1M
- Earl MartinTomball$6.2M
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.